Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3000-0.0300 (-1.29%)
At close: 04:00PM EDT
2.3700 +0.07 (+3.04%)
After hours: 05:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3300
Open2.3300
Bid2.2000 x 1300
Ask2.3700 x 800
Day's Range2.2700 - 2.3300
52 Week Range2.1500 - 10.5800
Volume28,385
Avg. Volume117,566
Market Cap43.277M
Beta (5Y Monthly)-0.01
PE Ratio (TTM)N/A
EPS (TTM)-1.7620
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.40
  • GlobeNewswire

    Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

    DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering priced at-the-market under Nasdaq rules with an institutional investor of an aggregate of (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompanying

  • American City Business Journals

    Novan preps to seek FDA approval for lead drug as competitor stumbles

    A Durham-based pharmaceutical company plans to raise $15 million as it prepares to seek regulatory approval for its treatment for a viral skin infection.

  • GlobeNewswire

    Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

    DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to sell to the investor, in a registered direct offering priced at-the-market under Nasdaq rules, (i) 2,080,696 shares of its common stock and accompanying warrants to purchase up to 2,080,696 shares of common stock and (ii) pre-funded warrants to purchase up to 3,180,615 shares of common stock and accompa

Advertisement
Advertisement